Sublingual Immunotherapy

Publication Date: May 1, 2017

Key Points

Key Points

  • It is crucial that the practicing allergist separate the data on FDA reviewed products that have led to approval of these products (ie, dust mites, grass and ragweed tablets) from the data in the literature with other allergens and other formulations (eg, liquid formulations) that have not undergone the rigor of FDA review.

Diagnosis

...Diagn...

...able 1. World Allergy Organization Grading...


Table 2. Description of Local Adverse Effects R...


Treatment

...Treatme...

...A-approved SLIT products for the tre...


...physician should be aware that SLIT...


...-approved SLIT products very cautiously in the pr...


...assume dosing equivalence between SLIT tablets an...


...he patient’s first dose of SLIT in a med...


...scribe epinephrine (either an auto...


...ce a patient’s SLIT dose if they have mi...


Schedule patients receiving SLIT therapy...


...d products for SLIT in the United State...


...ed Guidelines for the Practicing Allergist Regardi...


...e 4. FDA-Approved Sublingual Tablets...